Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women
|
|
- Ashley Arnold
- 6 years ago
- Views:
Transcription
1 European Journal of Endocrinology (2006) ISSN CLINICAL STUDY Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women Irene Lambrinoudaki 1, George Christodoulakos 1, Demetrios Rizos 2, Emmanuel Economou 2, John Argeitis 1, Sofia Vlachou 1, Maria Creatsa 1, Evangelia Kouskouni 2 and Dimitrios Botsis 1 1 2nd Department of Obstetrics and Gynecology, and 2 Hormonal and Biochemical Laboratory, University of Athens, Aretaieio Hospital, Athens, Greece (Correspondence should be addressed to I Lambrinoudaki, 27 Themistokleous Street, Dionysos, GR-14578, Athens, Greece; ilambrinoudaki@hotmail.com) Abstract Objective: To assess the association between endogenous sex hormones and risk factors for atherosclerosis in healthy postmenopausal women. Design: Cross-sectional study in a university menopause clinic. Methods: Serum sex hormones and lipid lipoprotein profile, arterial pressure, homocysteine and insulin resistance, measured by the homeostasis model assessment of insulin resistance (HOMA-IR), were assessed in 598 healthy postmenopausal women not on hormone therapy. Results: Compared with women in the lowest testosterone quartile (Q), women in the highest testosterone quartile had higher total cholesterol (Q1: 225.2G41.3 vs Q4: 246.2G38.4 mg/dl, P!0.01), low-density lipoprotein (LDL)-cholesterol (Q1: 146.9G37.2 vs Q4: 171.8G35.3 mg/dl, P!0.001), atherogenic index of plasma (AIP) (Q1: 0.224G0.238 vs Q4: 0.087G0.254, P!0.01), apolipoprotein B (ApoB) (Q1: 100.7G23.1 vs Q4: 113.9G23.8 mg/dl, P!0.001) and higher highdensity lipoprotein (HDL)-cholesterol (Q1: 60.7G14.5 vs Q4: 52.9G13.0 mg/dl, P!0.01). Accordingly, women in the highest free androgen index (FAI) quartile had higher AIP (Q1: 0.232G0.254 vs Q4: 0.078G0.243, P!0.001) and ApoB (Q1: 102.4G25.5 vs Q4: 114.2G 25.8 mg/dl, P!0.01) and lower HDL-cholesterol (Q1: 62.0G15.7 vs Q4: 51.9G11.6 mg/dl, P!0.001) and apolipoprotein A (Q1: 159.6G25.6 vs Q4: 147.9G24.1 mg/dl, P!0.01) compared with women in the lowest FAI quartile. These differences remained significant after adjustment for age, body mass index (BMI), insulin resistance and social habits. The free estrogen index (FEI) exhibited similar associations to the FAI. HOMA-IR showed an independent positive association with total testosterone (Q1: 2.00G1.36 vs Q4: 2.66G1.60, P!0.01), FAI (Q1: 1.70G1.12 vs Q4: 3.04G1.66, P!0.001) and FEI (Q1: 1.70G0.91 vs Q4: 3.08G1.77, P!0.001). Conclusions: Increased androgenicity in healthy postmenopausal women is associated with an unfavorable cardiovascular risk profile. High endogenous estradiol is related to a pro-atherogenic lipid profile, an association which may, in part, be mediated by insulin resistance. European Journal of Endocrinology Introduction Cardiovascular disease (CVD) is a leading cause of death of women worldwide. While premenopausal women have a lower incidence of CVD compared with men of the same age, the incidence of the disease in women rises steeply after the age of 50 (1). The association between menopause and CVD was indicated in the Framingham cohort, where postmenopausal women had a 2 6 times greater incidence of CVD compared with premenopausal women in the same age range (2). Furthermore, premature menopause caused by bilateral oophorectomy in younger women is an established risk factor for ischemic heart disease (3). Menopause is associated with a pro-atherogenic lipid profile characterized principally by lower high-density lipoprotein-cholesterol (HDL-cholesterol), higher low-density lipoproteincholesterol (LDL-cholesterol) and triglyceride levels (4), central adiposity (5), increased diastolic pressure (6) and increased insulin resistance (7). Sex steroid deficiency is considered a crucial factor responsible for the menopause-associated changes in the CVD risk factor profile, and consequently for the increase in CVD risk (8). Although the menopausal ovary does not secrete estrogens, it continues to serve as a source of androgens. To variable degrees, ovarian D 4 andostendione and testosterone are aromatized peripherally, mainly in the adipose tissue, to estrone and estradiol respectively, thus determining the postmenopausal endogenous estrogen milieu (9). In contrast to the established cardiovascular benefit of premenopausal sex steroids, little is known q 2006 Society of the European Journal of Endocrinology DOI: /eje Online version via
2 908 I Lambrinoudaki and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 about the effect of postmenopausal estrogens of endogenous origin on CVD risk. Concerning the association of endogenous estrogens with the lipid profile in postmenopausal women, studies have yielded conflicting results. Some authors have reported positive correlations between serum estrone or estradiol with HDL-cholesterol and triglycerides and inverse associations with total cholesterol and LDL-cholesterol (10 14), while others have reported higher total cholesterol (15) as well as lower triglycerides in women with higher endogenous estrogen levels (16). Finally, some investigators have found no significant association between estrogen and lipid levels (17 19). Moreover, although menopausal transition increases insulin resistance (20) and arterial pressure (21), no data exist as to whether fluctuations in circulating estradiol within the menopausal range have any impact on these parameters. The same discrepancy holds for homocysteine metabolism. It still remains to be clarified whether variation of endogenous estrogen levels may causatively inflict changes in homocysteine metabolism or whether this association is confounded by age or adiposity (22). The matter is further complicated when studying the effect of exogenous estrogens on CVD risk factors and incidence in postmenopausal women. Although ample evidence exists that exogenous estrogens improve lipid lipoprotein profile, insulin resistance, homocysteine metabolism, and vasodilation and that estrogens have anti-inflammatory properties at the vascular wall (21), the results of recent randomized controlled studies have revealed an increased risk of ischemic cardiac events in postmenopausal women treated with estrogen progestin therapy (23). Beyond estrogens, androgen status may also play an important role in determining the cardiovascular risk in postmenopausal women. The association of endogenous androgens with CVD risk factors and the incidence of cardiovascular events are even more perplexing. Androgen excess in premenopausal women, as is the case in polycystic ovary syndrome (PCOS), has been associated with increased triglycerides and small, dense LDL particles, as well as reduced HDL-cholesterol (24, 25). Furthermore, hyperandrogenemic women demonstrate increased insulin resistance and incidence of CVD (26, 27). In contrast to the established negative impact of premenopausal hyperandrogenicity on the cardiovascular system, little is known on the effect of postmenopausal endogenous androgens on CVD risk. Increased testosterone levels in healthy postmenopausal women have been related to a risk factor profile which resembles that of hyperandrogenemic PCOS women (28), although these findings have not been corroborated by others (29). On the contrary, several recent studies have demonstrated that postmenopausal women with reduced circulating testosterone have an increased incidence of CVD, independent of metabolic factors (30, 31). Similarly, postmenopausal women with testosterone levels in the highest tertile demonstrated significantly lower intimal-medial thickness of carotid wall compared with women in the lower testosterone tertiles (32). Given the discrepancy in data on the association of endogenous sex steroids with cardiovascular risk factors in postmenopausal women and due to the possibility that the knowledge of this association may aid the clinician in the evaluation of postmenopausal women who are candidates for estrogen or androgen therapy, we undertook the present study in order to evaluate the association of endogenous sex steroids with the lipid lipoprotein profile, insulin resistance, homocysteine levels and arterial pressure in healthy postmenopausal women of Greek origin. Subjects and methods Subjects Subjects were recruited from the Menopause Clinic of the 2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital. This study was part of a survey aiming to evaluate risk factors for menopause-associated diseases in community-dwelling Greek women on their first counseling visit to our Menopause Clinic. For this purpose 1278 women were recruited during the time period from November 1998 to June Data reported in this study are based on 598 women for whom hormone measurements were available. Participants were at least 1 year postmenopausal and were not current users of hormone therapy. Ex-users were not included in the study unless they had been off therapy for at least 6 months. All women had a gynecological and biochemical evaluation which included: bimanual examination, PAP smear and transvaginal sonography, breast examination and mammography, thyroid liver renal function as well as blood coagulation tests and bone densitometry. Criteria for inclusion in the study were a sonographically assessed endometrial thickness %5 mm and the absence of gynecological malignancy, arterial hypertension, ischemic heart disease, thromboembolism, diabetes mellitus and non-treated thyroid dysfunction. Women on lipid-lowering or antihypertensive medication were not included in the study. Finally, women with abnormally high testosterone or dehydroepiandrosterone sulfate (DHEAS), as well as women with triglyceride levels above 400 mg/dl, were also excluded. All subjects signed an informed consent, and Institutional Review Board approval was obtained by the Ethics Committee of Aretaieion Hospital. Protocol Participating women were evaluated in a crosssectional design. A detailed medical history was
3 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 recorded for every subject. Blood pressure, weight and height were measured in the morning, in light clothing, and body mass index (BMI) was computed. Subsequently, fasting blood samples were drawn at 0900 h for the determination of serum lipids, lipoproteins, homocysteine and hormones. Samples were centrifuged immediately and serum was stored at K80 8C until assayed. Biochemical assays Serum total cholesterol, HDL-cholesterol and triglycerides were assessed enzymatically by an autoanalyzer (COBAS-MIRA, Roche Diagnostics Limited, Lewes, East Sussex, UK). LDL-cholesterol was estimated as described by the Friedewald equation (LDL-cholesterolZtotal cholesterol triglycerides/5 HDL-cholesterol). Apolipoprotein A1 (ApoA), apolipoprotein B (ApoB) and lipoprotein a (Lp(a)) were determined by an immunoturbimetric assay (ABX Diagnostics BP Montpellier, France). The atherogenic index of plasma (AIP) was computed by the following equation: log [triglycerides (mmol/l)/hdl-cholesterol (mmol/l)] (34). Serum homocysteine levels were measured by the Abbott Imx Homocysteine kit (Abbott Laboratories, Abbott Park, IL, USA). The total coefficient of variation (CV) (%) and the sensitivity of the kit were 4.3% and 0.5 mmol/l respectively. Hormone assays Follicle-stimulating hormone (FSH) was measured with the Microparticle Enzyme Immunoassay kit: FSH, Abbott Axsym measured on the AxsymR analyzer (Abbott Laboratories). The total CV ranged from 5.3% to 8.5%. Estradiol was measured with a commercial Enzyme Immunoassay kit: DSK (Diagnostic Systems Laboratories Inc., Webster, TX, USA). The total CV ranged from 4.3% to 6.1% and the analytical sensitivity was 8 pg/ml. D 4 -Androstendione was measured with an IBL Androstendione ELISA kit (IBL GmbH, Hamburg, Germany). The inter-assay CV ranged from 6.5% to 8.1%. Total testosterone and DHEA-SO4 were measured with DPC Total Testosterone and DHEA-SO4 Immulite analyzer kits (Diagnostic Products Corporation, Los Angeles, CA, USA). The total CV ranged from 8.0% to 16.0% and from 8.1% to 15% respectively. Sex hormone-binding globulin (SHBG) concentrations were measured with a DPC Immulite SHBG chemiluminescent enzyme immunometric assay kit (Diagnostic Products Corporation). The total CV ranged from 4.1% to 9.2%. The free estrogen index (FEI) was calculated using total estradiol and SHBG values by the following equation: FEIZestradiol (pg/ml)! 0.367/SHBG (nmol/l). The free androgen index (FAI) was calculated using total testosterone and SHBG values by the following equation: FAIZtestosterone (ng/ml)!3.47!100/shbg (nmol/l). Insulin was Postmenopausal sex hormones and cardiovascular risk factors 909 measured by an Abbott Insulin kit on an IMx analyzer (Abbott Laboratories). The total CV ranged from 4.4% to 6.0%. Insulin resistance was calculated by homeostasis model assessment of insulin resistance (HOMA-IR), based on fasting insulin and glucose levels, using the following equation: HOMA-IRZinsulin (mu/ml)!glucose (mmol/l)/22.5. Statistical analysis Statistical analysis was performed by use of SPSS version 8.0 (Statistical Package for the Social Sciences, Chicago, IL, USA). Distributions of continuous variables were tested for normality by use of the Kolmogorov Smirnov test. Skewed variables were logarithmically transformed. Means of lipids, lipoproteins, atherogenic index of plasma (AIP), HOMA, systolic and diastolic arterial pressure and serum homocysteine were compared across quartiles of serum hormones by ANOVA and were tested for linear trends. Adjustments for possible confounding factors were performed by multiple regression analysis. Statistical significance was set at the 0.05 level. Results The baseline characteristics of the 598 women participating in the study are presented in Table 1. Triglycerides, Lp(a), FSH, sex hormones and insulin had a skewed distribution and thus were logarithmically transformed for further statistical analysis. Tables 2 and 3 present the mean levels of lipids, AIP, lipoproteins, systolic and diastolic arterial pressure, HOMA-IR and homocysteine according to hormone quartiles. Triglycerides, AIP, ApoB, blood pressure and HOMA-IR decreased while HDL and ApoA increased from the lower to the highest FSH quartile. Women in quartile 1 had mean AIP levels of compared with in women in the highest quartile (P for linear trend Z0.0001). Accordingly, women in the first quartile had mean HOMA-IR levels of 2.74 compared with 1.82 in women in the 4th quartile (P for trend Z0.0001). In contrast to exogenously administered estrogen, the FEI associated positively with AIP, ApoB, blood pressure and HOMA-IR. Women in the lowest FEI quartile had mean AIP levels of compared with in women in the highest FEI quartile (P for linear trend Z0.0001). Accordingly, mean HOMA-IR levels were 1.70 in women in the lowest FEI quartile compared with 3.08 in women in the highest FEI quartile (P for linear trend Z0.0001). Testosterone showed a strong positive association with total and LDL-cholesterol (Fig. 1), triglycerides, AIP, ApoB and HOMA-IR, and a negative association with HDLcholesterol and ApoA (Tables 2 and 3). Mean AIP was K0.224 in the lowest testosterone quartile compared with K0.087 in the highest quartile (P for linear trend Z0.001). Accordingly, mean HOMA-IR levels increased from 2.00 in the lowest to 2.66 in the highest
4 910 I Lambrinoudaki and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 Table 1 Baseline demographic characteristics of the 598 healthy postmenopausal women who participated in the study. Continuous variables Mean S.D. Min Max Age (years) YSM BMI (kg/m 2 ) Systolic AP Diastolic AP Cholesterol (mg/dl) Triglycerides (mg/dl) HDL (mg/dl) LDL (mg/dl) Lp(a) (mg/dl) ApoA1 (mg/dl) ApoB (mg/dl) FSH (miu/ml) Estradiol (pg/ml) Testosterone (ng/ml) D 4 A (ng/dl) DHEAS (ng/dl) SHBG (nmol/l) HOMA-IR Homocysteine (mmol/l) Categorical variables Smoking (current, O10 22 cigarettes/day) (%) Daily alcohol intake (%) 0.8 Physical exercise (O 1 h/week) (%) 18.3 YSM: years since menopause, BMI: body mass index; AP: arterial pressure; D 4 A: D 4 -Androstendione; DHEAS: dehydroepindrosterone sulfate; SHBG: sex hormone-binding globulin; HOMA-IR: homeostasis model assessment of insulin resistance. testosterone quartile (P for linear trendz0.01). The FAI exhibited the same associations as total testosterone (Figs 1and 2). Mean AIP increasedfrom K0.232 in the lowest FAI quartile to K0.078 in the highest FAI quartile (P for linear trendz0.0001). Likewise, mean HOMA-IR increased from 1.70 in the lowest quartile to 3.04 in the highest (P for linear trendz0.0001). SHBG exhibited strong negative associations with triglycerides, AIP, ApoB, systolic and diastolic arterial pressure and HOMA-IR (Fig. 2). There was a significant decrease in AIP (K0.104 in quartile 1 vs K0.248 in quartile 4, P for linear trendz0.0001), in triglycerides (106.3 mg/dl in quartile 1 vs 82.6 mg/dl in quartile 4, P for linear trendz0.001), in ApoB (111.4 mg/dl in quartile 1 vs mg/dl in quartile 4, P for linear trendz0.02), in systolic arterial pressure (AP) (122.6 mmhg in quartile 1 vs mmhg in quartile 4, P for linear trendz0.005), in diastolic AP (79.5 mmhg in quartile 1 vs 70.5 mmhg in quartile 4, P for linear trendz0.001) and in HOMA-IR (3.11 in quartile 1 vs 1.54 in quartile 4, P for linear trendz ) by moving from the lower to the higher SHBG quartile. In contrast, there was an increase in HDL (53.4 mg/dl in quartile 1 vs 61.5 mg/dl in quartile 4, P for linear trendz0.0001) and ApoA (151.7 mg/dl in quartile 1 vs mg/dl in quartile 4, P for linear trendz0.002) across increasing SHBG quartiles. D 4 A and DHEAS did not associate with lipids, lipoproteins, arterial pressure, homocysteine or HOMA-IR. The results of the multivariate analysis on the relation between hormones and lipids, lipoproteins, arterial pressure, HOMA-IR and homocysteine are presented in Table 4. Besides hormones, the model included age, BMI, current cigarette smoking, alcohol consumption and physical exercise as independent variables. After adjustments for the above-mentioned covariates, FSH showed a significant negative association with triglycerides, AIP, diastolic arterial pressure and HOMA-IR and a positive association with HDLcholesterol and ApoA. Furthermore, while estradiol showed a negative association only with Lp(a), FEI associated marginally positively with triglycerides, significantly positively with AIP and HOMA-IR, and negatively with HDL and ApoA. Both testosterone and FAI showed a strong positive association with total and LDL-cholesterol, triglycerides, AIP, ApoB and HOMA-IR and a negative association with HDL-cholesterol, Lp(a) (testosterone) and ApoA (FAI) (Table 4). Contrariwise, SHBG associated negatively with triglycerides, AIP, ApoB, systolic and diastolic arterial pressure and HOMA-IR and positively with HDL-cholesterol and ApoA. D 4 A associated positively with LDL-cholesterol and AIP and negatively with HDLcholesterol, but these associations were weaker compared with those of testosterone. DHEAS did not associate with lipids, lipoproteins, arterial pressure, HOMA-IR or homocysteine. Discussion The results of our study suggest that healthy postmenopausal women with a higher index of androgenicity, indicated by higher total testosterone, higher FAI and lower SHBG, exhibit a pro-atherogenic risk profile, characterized by lower HDL-cholesterol and higher triglycerides, AIP, insulin resistance and diastolic blood pressure. Our findings are in concordance with previous reports examining the association between serum androgens and lipid profile in postmenopausal women. Haffner et al. (35), in a population study of 253 community-dwelling postmenopausal women, concluded that total testosterone correlated positively with total cholesterol, while free testosterone related inversely to HDL-cholesterol. Furthermore, Shelley et al. reported a positive independent association of the FAI with LDL-cholesterol, but not with HDL-cholesterol or triglycerides (10). It has to be borne in mind, however, that Shelley et al. evaluated menopausal transition, and their population, therefore, comprised both pre- and postmenopausal women. In a small sample of Japanese postmenopausal women, free testosterone predicted total and LDL-cholesterol, HDL-cholesterol
5 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 Postmenopausal sex hormones and cardiovascular risk factors 911 Table 2 Mean (S.D.) levels of serum lipids, the atherogenic index of plasma (AIP) and lipoprotein (a) according to hormone quartiles (Q) in 598 healthy postmenopausal women. TC (mg/dl) Triglycerides (mg/dl) LDL (mg/dl) HDL (mg/dl) AIP Lipoprotein (a) (mg/dl) FSH (miu/ml) Q1 ( ) (44.5) (52.6) (40.3) 55.9 (12.8) K0.125 (0.262) 16.6 (16.4) Q2 ( ) (37.8) (49.8) (34.6) 57.9 (12.5) K0.157 (0.247) 18.8 (21.5) Q3 ( ) (38.8)) 92.9 (40.9) (37.7) 58.2 (13.4) K0.173 (0.230) 23.1 (24.5) Q4 ( ) (43.1) 85.2 (38.3)*** (39.6) 62.8 (14.3)*** (0.230)*** 15.8 (15.7) Estradiol (pg/ml) Q1 ( ) (40.4) 94.7 (46.4) (38.4) 60.5 (14.6) K0.188 (0.254) 23.9 (25.5) Q2 ( ) (42.7) 97.9 (46.7) (39.1) 59.8 (13.0) K0.179 (0.240) 16.1 (17.1) Q3 ( ) (43.0) (53.5) (38.6) 55.4 (12.5) K0.135 (0.251) 15.9 (17.6) Q4 ( ) (38.9) 92.1 (39.8) (35.6)* 57.5 (13.3)* K0.189 (0.243) 17.7 (17.7)* Testosterone (ng/ml) Q1 ( ) (41.3) 86.5 (43.1) (37.2) 60.7 (14.5) K0.224 (0.238) 19.3 (21.4) Q2 ( ) (37.5) 93.6 (43.2) (34.6) 58.4 (12.3) K0.186 (0.223) 18.1 (23.5) Q3 ( ) (45.0) 91.1 (36.7) (40.9) 59.2 (13.9) K0.195 (0.227) 13.0 (14.7) Q4 ( ) (38.4)** (56.4)** (35.3)*** 52.9 (13.0)** K0.087 (0.254)** 16.6 (20.8) D 4 A (ng/dl) Q1 ( ) (45.2) 95.6 (46.5) (41.2) 59.6 (14.1) K0.199 (0.234) 15.3 (20.9) Q2 ( ) (37.7) 92.8 (40.0) (36.2) 57.1 (11.9) K0.176 (0.240) 14.0 (16.2) Q3 ( ) (40.3) 93.3 (45.8) (38.8) 55.2 (13.2) K0.158 (0.253) 13.2 (14.1) Q4 ( ) (41.9) 93.1 (37.8) (34.1) 56.8 (14.1) K0.169 (0.215) 18.2 (19.8) DHEAS (ng/dl) Q1 ( ) (40.1) (57.5) (35.4) 58.9 (12.1) K0.171 (0.258) 19.9 (24.0) Q2 ( ) (39.1) 93.7 (39.3) (38.4) 59.4 (13.3) K0.180 (0.238) 17.7 (18.4) Q3 ( ) (37.6) 98.9 (47.4) (36.1) 56.4 (13.0) K0.150 (0.251) 12.3 (13.8) Q4 ( ) (42.0) 95.6 (42.1) (37.3) 57.6 (13.3) K0.165 (0.235) 21.3 (20.0) SHBG (nmol/l) Q1 ( ) (41.1) (50.6) (36.9) 53.4 (12.2) K0.104 (0.229) 18.6 (21.1) Q2 ( ) (45.4) 94.8 (44.3) (43.5) 58.2 (13.6) K0.177 (0.255) 21.0 (25.0) Q3 ( ) (39.9) 92.9 (45.8) (36.3) 59.2 (13.6) K0.192 (0.238) 14.1 (16.5) Q4 ( ) (36.6) 82.6 (27.1)** (34.5) 62.5 (14.6)*** K0.248 (0.213)*** 16.0 (18.5) FAI Q1 ( ) (42.4) 86.5 (44.4) (37.7) 62.0 (15.7) K0.232 (0.254) 16.0 (18.1) Q2 ( ) (33.8) 88.7 (31.5) (31.4) 60.7 (11.6) K0.214 (0.203) 19.8 (24.8) Q3 ( ) (44.5) 92.3 (42.0) (44.1) 58.1 (13.5) K0.189 (0.230) 12.7 (12.9) Q4 ( ) (41.9)* (53.8)** (36.2)** 51.9 (11.6)*** K0.078 (0.247)*** 16.9 (21.9) FEI Q1 ( ) (38.0) 86.6 (31.2) (36.4) 64.0 (14.5) K0.237 (0.213) 20.8 (27.0) Q2 ( ) (40.4) 87.6 (43.2) (36.0) 60.6 (14.5) K0.224 (0.238) 16.4 (19.7) Q3 ( ) (42.1) (53.4) (40.1) 54.5 (11.2) K0.123 (0.233) 17.3 (19.4) Q4 ( ) (42.0) 95.5 (39.7) (38.4) 55.5 (13.0)*** K0.153 (0.252)*** 15.9 (14.8) *P!0.05, **P!0.01, ***P!0.001 (P for linear trend, ANOVA). D 4 A: D 4 -Androstendione; DHEAS: dehydroepindrosterone sulfate; SHBG: sex hormonebinding globulin. and triglycerides independently of insulin resistance and BMI (18). Similarly, bioavailable testosterone has been reported as an independent predictor of VLDL-TG (36). Very recently, a study conducted on a selected sample from the Atherosclerosis Risk in Communities (ARIC) population (15) revealed that the FAI was positively associated with higher LDL-cholesterol levels independently of demographic and metabolic factors and health behaviors. In contrast to total and free testosterone, SHBG, in our study as well as in other studies, associated with a favorable lipid profile. SHBG is secreted by the liver and binds testosterone, dihydrotestosterone and estradiol with high affinity, thus regulating their free concentrations (37). Haffner et al. (38) have hypothesized that SHBG may reflect intracellular bioavailable testosterone better than total testosterone, with reduced SHBG expressing greater androgenicity. Insulin is also considered an important inhibitor of SHBG production (37). SHBG has been shown consistently to relate positively to HDL-cholesterol (15, 35, 39) and negatively to triglycerides, total and LDL-cholesterol (15), as well as to ApoB (18). Contrariwise, two small studies have not found an association between endogenous testosterone or SHBG and lipid profile in postmenopausal women (19, 39). Our study is the first to demonstrate a positive association between the AIP and indexes of androgenicity in postmenopausal women. The AIP, defined as the logarithm of the ratio TG:HDL-cholesterol, has recently been proposed as a marker of the atherogenic potential of plasma. The significance of the AIP as a marker is based on the fact that (a) it is found increased in cohorts at high risk for coronary artery disease, (b) it is
6 912 I Lambrinoudaki and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 Table 3 Mean levels of serum apolipoproteins, systolic and diastolic adrenal pressure (AP), HOMA-IR and homocysteine (Hcy) according to hormone quartiles in 598 healthy postmenopausal women. ApoA1 (mg/dl) ApoB (mg/dl) Systolic AP Diastolic AP HOMA-IR Hcy (mg/dl) FSH (miu/ml) Q1 ( ) (28.9) (25.9) (9.5) 79.8 (8.1) 2.74 (1.84) 11.2 (2.78) Q2 ( ) (27.8) (25.2) (10.1) 75.2 (7.7) 2.33 (1.33) 10.7 (2.28) Q3 ( ) (25.3) (25.1) (10.1) 75.3 (10.1) 2.20 (1.28) 11.0 (2.52) Q4 ( ) (27.8)** (25.3)* (7.2)* 73.1 (8.8)* 1.82 (1.00)*** 11.5 (2.94) Estradiol (pg/ml) Q1 ( ) (31.6) (25.9) (8.85) 79.4 (8.27) 2.05 (1.22) 10.1 (2.30) Q2 ( ) (25.8) (24.8) (9.92) 74.7 (9.60) 2.24 (1.49) 11.4 (2.80) Q3 ( ) (25.9) (27.7) (10.6) 73.8 (8.75) 2.22 (1.04) 11.0 (2.07) Q4 ( ) (26.8) (24.0) (8.13) 76.9 (8.45) 2.51 (1.67)* (2.85) Testosterone (ng/ml) Q1 ( ) (25.6) (23.1) (11.2) 75.0 (11.0) 2.00 (1.36) 11.6 (2.72) Q2 ( ) (28.0) (20.8) (10.0) 78.1 (6.67) 2.06 (1.00) 11.4 (2.69) Q3 ( ) (23.6) (28.7) (7.61) 75.0 (7.40) 2.14 (1.09) 11.2 (2.37) Q4 ( ) (22.7)* (23.8)*** (5.77) 72.5 (10.6) 2.66 (1.60)** 10.8 (2.48) D 4 A (ng/dl) Q1 ( ) (24.0) (25.4) (6.19) 74.4 (8.73) 2.21 (1.33) 11.2 (2.68) Q2 ( ) (24.6) (23.8) (9.35) 74.4 (10.9) 2.32 (1.66) 11.2 (2.44) Q3 ( ) (23.3) (25.9) (9.81) 74.4 (8.92) 2.18 (1.49) 10.9 (2.42) Q4 ( ) (28.0) (26.0) (11.7) 76.7 (9.63) 2.49 (1.35) 11.8 (3.01) DHEAS (ng/dl) Q1 ( ) (27.7) (26.8) (10.8) 73.7 (10.0) 2.15 (1.62) 11.0 (2.50) Q2 ( ) (29.6) (24.1) (9.5) 76.2 (10.2) 2.23 (1.55) 11.3 (2.86) Q3 ( ) (27.0) (26.1) (9.67) 73.3 (9.07) 2.43 (1.42) 11.0 (2.13) Q4 ( ) (27.5) (26.5) (9.63) 77.7 (7.52) 2.25 (1.20) 11.6 (2.83) SHBG (nmol/l) Q1 ( ) (25.3) (24.8) (8.89) 79.5 (8.05) 3.11 (1.76) 10.7 (2.73) Q2 ( ) (22.9) (24.6) (7.99) 77.3 (8.20) 2.25 (1.22) 11.2 (2.40) Q3 ( ) (27.8) (23.7) (6.50) 74.2 (9.10) 1.97 (0.85) 11.1 (2.35) Q4 ( ) (24.9)** (26.0)* (11.4)** 70.5 (9.74)** 1.54 (0.75)*** 11.3 (2.95) FAI Q1 ( ) (25.6) (25.5) (11.1) 71.9 (9.87) 1.70 (1.12) 11.6 (2.91) Q2 ( ) (30.3) (23.2) (8.79) 77.0 (8.60) 1.83 (0.88) 11.4 (2.43) Q3 ( ) (19.2) (24.9) (7.99) 77.3 (9.61) 2.23 (1.08) 10.7 (1.92) Q4 ( ) (24.1)** (25.8)** (8.12) 76.7 (8.17) 3.04 (1.66)*** 11.1 (2.76) FEI Q1 ( ) (25.7) (24.5) (10.7) 71.5 (9.88) 1.70 (0.906) (2.88) Q2 ( ) (24.7) 99.9 (23.5) (9.0) 75.3 (10.6) 1.96 (0.990) (2.76) Q3 ( ) (20.8) (24.9) (8.5) 74.1 (8.61) 2.17 (1.17) (1.98) Q4 ( ) (27.4)*** (26.1)* (8.8)* 79.2 (7.02)** 3.08 (1.77)*** (2.85) *P!0.05, **P!0.01, ***P!0.001 (P for linear trend, ANOVA). D 4 A: D 4 -Androstendione; DHEAS: dehydroepindrosterone sulfate; SHBG: sex hormonebinding globulin; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance. positively correlated with the fractional esterification rate of HDL-cholesterol, which is perhaps the most dependable marker for the atherogenic capacity of the lipid lipoprotein profile, and (c) it is inversely correlated to LDL-cholesterol particle size (40, 41). In our study, higher total testosterone and FAI levels as well as lower SHBG were associated with increased insulin resistance. Free testosterone has been reported to associate positively with fasting plasma glucose and insulin levels (42 44), as well as with the insulin/ glucose ratio (45). In the more recent evaluation of the Rancho Bernando cohort, Oh et al. (42) showed that, after adjusting for age, adiposity and systolic blood pressure, elevated free testosterone predicted longitudinally higher insulin levels and HOMA-IR as well as incident type 2 diabetes mellitus. Furthermore, Golden et al., studying the ARIC population (46), concluded that hyperandrogenism in postmenopausal women most strongly associated with the glucose and insulin component of the metabolic syndrome. SHBG showed an independent negative association with diastolic blood pressure in our study. Earlier reports have indicated that androgen levels are higher in women with essential hypertension (47). Haffner et al. (35) reported a positive association between endogenous total testosterone and systolic and diastolic blood pressure in postmenopausal women. Furthermore, hypertensive postmenopausal women are reported to have higher mean testosterone and free-to-total testosterone ratio compared with normotensive women (48). The same group demonstrated a significant association between free testosterone and blood pressure in healthy and diabetic postmenopausal women (49). Finally, Golden et al. reported that healthy postmenopausal women
7 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 Postmenopausal sex hormones and cardiovascular risk factors 913 r = 0.46, P = r = 0.19, P = r = 0.23, P = r = 0.44, P = Figure 1 Linear regression analysis of LDL-cholesterol to lntransformed serum testosterone (top) and of the atherogenic index of plasma (AIP) to the ln-transformed free androgen index (FAI) (bottom). Figure 2 Linear regression analysis of ln-transformed Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) to lntransformed serum sex hormone-binding globulin (SHBG) (top) and ln-transformed free androgen index (FAI) (bottom). of the ARIC population with an FAI in the highest quartile were nine times more likely to present with the metabolic syndrome compared with women in the lowest FAI quartile (46). In keeping with this finding, results from the SWHAN study, based on 2961 perimenopausal women, indicated that SHBG was associated strongly and inversely with the metabolic syndrome (50). From all the above information it is apparent that increased androgenicity in postmenopausal women is associated with an increased risk for CVD. Contrary to this assumption, however, are the results of other studies, suggesting that postmenopausal women with low testosterone levels have increased carotid atherosclerosis (32) and increased incidence of coronary events (30, 31). A possible explanation for this discrepancy is that optimal cardiovascular function requires a certain range of circulating testosterone. Lower levels of testosterone may compromise endothelial function and blood viscosity (46), while higher levels may be associated with a constellation of atherogenic risk factors, namely increased visceral adiposity, increased blood pressure, insulin resistance and a pro-atherogenic lipid profile, as demonstrated in our study. It should be remembered, however, that testosterone in postmenopausal women is a precursor for estradiol and it may actually be estrogen deficiency that hides behind the association of low testosterone and increased CVD incidence. In keeping with the effect of higher androgens, higher estradiol levels associated with higher triglycerides, AIP, ApoB and lower HDL-cholesterol and ApoA. In keeping with our results, Mudali et al. (15) recently reported a strong positive association between estrone and total cholesterol and triglycerides among postmenopausal women with significant carotid atherosclerosis. Contrariwise, Ossewaarde et al. (16) demonstrated a significant
8 914 I Lambrinoudaki and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 Table 4 Linear regression analysis evaluating the association between serum lipids, lipoproteins, the atherogenic index of plasma, arterial pressure, HOMA-IR and serum hormones in 598 healthy postmenopausal women. The model is adjusted for age, BMI, cigarette smoking, alcohol intake and physical exercise. Ln-transformed hormones b coefficient P value Ln-transformed hormones b coefficient P value Total cholesterol Apolipoprotein A FSH K FSH Estradiol Estradiol K Testosterone Testosterone K D 4 A D 4 A DHEAS DHEAS SHBG K SHBG FAI FAI K FEI FEI K Triglycerides Apolipoprotein B FSH K FSH K Estradiol K Estradiol K Testosterone Testosterone D 4 A D 4 A DHEAS DHEAS SHBG K SHBG K FAI FAI FEI FEI LDL cholesterol Systolic AP FSH K FSH K Estradiol Estradiol K Testosterone Testosterone K D 4 A D 4 A DHEAS DHEAS SHBG K SHBG K FAI FAI FEI FEI HDL cholesterol Diastolic AP FSH FSH K Estradiol K Estradiol K Testosterone K Testosterone K D 4 A K D 4 A DHEAS K DHEAS SHBG SHBG K FAI K FAI FEI K FEI AIP HOMA-IR FSH K FSH K Estradiol K Estradiol Testosterone Testosterone D 4 A D 4 A DHEAS DHEAS K SHBG K SHBG K FAI FAI FEI FEI Lp(a) Homocysteine FSH K FSH K Estradiol K Estradiol Testosterone K Testosterone K D 4 A D 4 A DHEAS DHEAS SHBG K SHBG K FAI K FAI K FEI K FEI D 4 A: D 4 -Androstendione; DHEAS: dehydroepindrosterone sulfate; SHBG: sex hormone-binding globulin; HOMA-IR: homeostasis model assessment of insulin resistance; AP: arterial pressure. positive association between plasma estrone and HDLcholesterol, and a negative association with triglycerides and very low-density lipoprotein-cholesterol in a small sample of healthy postmenopausal women. Finally, other investigators found no significant association between endogenous estrogens and lipid levels or other markers of atherosclerosis (10, 17 19, 39, 51). Variability in the health status of the study population,
9 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154 as well as in the estrogen measured, is a possible reason for the discordant results. Many studies employed estrone as a marker of endogenous estrogen levels, which may be more representative in the postmenopausal population compared with estradiol, which is the principal premenopausal sex steroid. In our sample, 6% of the women had estradiol levels below 8 pg/ml, which is the analytical sensitivity of the assay employed, while 51% of the sample had estradiol values lying between 8 pg/ml and 20 pg/ml. Unfortunately, an ultra-sensitive estradiol assay with sensitivity below 5 pg/ml was not available. Furthermore, metabolic parameters that were not accounted for in the previous studies may have confounded the associations of lipids and lipoproteins with endogenous estrogens. In our study, adjustment for HOMA-IR removed many of the associations between atherogenic risk factors and endogenous estradiol, thus indicating that these associations are not causative but are probably mediated through metabolic factors insulin resistance being one of them. Certain limitations should be kept in mind when interpreting our data. First, our study was conducted on a clinic-based sample, a fact implying that our population may have been more motivated and health concerned compared with the community-dwelling women. Secondly, as pointed out above, we were not able to measure estrone, the predominant circulating estrogen in postmenopausal women. Thirdly, in being cross-sectional in design, our study does not permit the inference of causal associations between sex steroids and cardiovascular risk factors. The present study has several strengths. We were able simultaneously to examine the association of multiple cardiovascular risk factors such as lipids, lipoproteins, insulin resistance, blood pressure and homocysteine with both androgen and estrogen status in a large sample, comprising healthy postmenopausal women. As is the case with premenopausal women with androgen excess, endogenous androgenicity in postmenopausal women seems to relate to an unfavorable cardiovascular risk profile. Since androgen replacement therapy is increasingly being used for the treatment of sexual dysfunction and decreased well-being in postmenopausal women, its impact on lipid and metabolic parameters related to cardiovascular health should be studied thoroughly. References 1 Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW & Wing RR. Menopause and risk factors for coronary heart disease. The New England Journal of Medicine Kannel WB, Hjortland MC, McNamara PM & Gordon T. Menopause and risk of cardiovascular disease. The Framingham study. Annals of Internal Medicine Postmenopausal sex hormones and cardiovascular risk factors Barrett-Connor E & Bush TL. Estrogen and coronary heart disease in women. The Journal of the American Medical Association Warren PM & Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Practice and Research Clinical Endocrinology and Metabolism Avgoulea A, Mastorakos G, Lambrinoudaki I, Christodoulakos G & Creatsas G. Role of postmenopausal hormone replacement therapy on body fat gain and leptin levels. Gynecological Endocrinology Reckelhoff JF. Basic research into the mechanisms responsible for postmenopausal hypertension. International Journal of Clinical Practice (Suppl) Wu SI, Chou P & Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. Journal of Clinical Epidemiology Liu Y, Ding J, Bush TL, Longenecker JC, Nieto FJ, Golden SH & Szklo M. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. American Journal of Epidemiology Schiff I. Menopause. In Principles and Practice of Endocrinology and Metabolism. 2nd edn, pp Ed. KL Becker. Philadelphia, PA: JB Lippincott, Shelley JM, Green A, Smith AM, Dudley E, Dennerstein L, Hopper J & Burger H. Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Annals of Epidemiology Kuller LH, Gutai JP, Meilahn E, Matthews KA & Plantinga P. Relationship of endogenous sex steroid hormones to lipids and apoproteins in postmenopausal women. Arteriosclerosis Svendsen OL, Hassager C & Christiansen C. Relationships and independence of body composition, sex hormones, fat distribution and other cardiovascular risk factors in overweight postmenopausal women. International Journal of Obesity and Related Metabolic Disorders Soler JT, Folsom AR, Kaye SA & Prineas RJ. Associations of abdominal adiposity, fasting insulin, sex hormone binding globulin, and estrone with lipids and lipoproteins in postmenopausal women. Atherosclerosis Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O & Labate AM. Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status, Virgilio-Menopause-Health Group. Metabolism Mudali S, Dobs AS, Ding J, Jingzhong D, Cauley JA, Moyses S & Golden SH. Endogenous postmenopausal hormones and serum lipids: the Atherosclerosis Risk in Communities Study. Journal of Clinical Endocrinology and Metabolism Ossewaarde ME, Bots ML, van der Schouw YT, Thijssen JHH, Westerveld T, de Jong FH & Grobbee DE. Plasma and urinary sex hormones are differently related to lipids in healthy postmenopausal women. Maturitas Cauley JA, Gutai JP, Glynn NW, Paternostro-Bayles M, Cottington E & Kuller LH. Serum estrone concentrations and coronary artery disease in postmenopausal women. Arteriosclerosis and Thrombosis Kumagai S, Kai Y & Sasaki H. Relationship between insulin resistance, sex hormones and sex hormone-binding globulin in the serum lipid and lipoprotein profiles of Japanese postmenopausal women. Journal of Atherosclerosis and Thrombosis Cauley JA, Gutai JP, Kuller LH & Powell JG. The relation of endogenous sex steroid hormone concentrations to serum lipid and lipopoprotein levels in postmenopausal women. American Journal of Epidemiology Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D & Creatsas G. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. Maturitas
10 916 I Lambrinoudaki and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) Dubey RK, Imthurn B, Barton M & Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovascular Research Christodoulakos GE, Panoulis CP, Rizos D, Moustakarias T, Phocas I & Creatsas G. Homocysteine and folate levels in postmenopausal women. Maturitas The Writing Group for the Women s Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. The Journal of the American Medical Association Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS & Clayton RN. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism Pirwany IR, Fleming R, Greer IA, Packard CJ & Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clinical Endocrinology Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR & Buring JE. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation Reinecke H, Bogdanski J, Woltering A, Breithardt G, Assmann G, Kerber S & von Eckardstein A. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. American Journal of Cardiology Wild S, Pierpoint T, McKeigue P & Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology Bernini GP, Sgro M, Moretti A, Argenio GF, Barlascini CO, Cristofani R & Salvetti A. Endogenous androgens and carotid intimal-medial thickness in women. Journal of Clinical Endocrinology and Metabolism Kaczmarek A, Reczuch K, Majda J, Banasiak W & Ponikowski P. The association of lower testosterone level with coronary artery disease in postmenopausal women. International Journal of Cardiology Rako S. Testosterone deficiency: a key factor in the increased cardiovascular risk to women following hysterectomy or with natural aging? Journal of Women s Health Bernini GP, Moretti A, Sgro M, Argenio GF, Barlascini CO, Cristofani R & Salvetti A. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause Hoffmann GE, Hiefinger R & Weiss L. Five methods for measuring low-density lipoprotein cholesterol concentration in serum compared. Clinical Chemistry Tan MH, Johns D & Glazer BN. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clinical Chemistry Haffner SM, Newcomb PA, Marcus PM, Klein BE & Klein R. Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA-SO4) to cardiovascular risk factors in postmenopausal women. American Journal of Epidemiology Van Beek AP, de Ruijter-Heijstek FC, Jansen H, Erkelens DW & de Bruin TW. Sex steroids and plasma lipoprotein levels in healthy women: The importance of androgens in the estrogen-deficient state. Metabolism Rosner W. Plasma steroid-binding proteins. Endocrinology and Metabolism Clinics of North America Haffner SM, Katz MS & Dunn JF. Increased upper body and overall adiposity is associated with decreased sex hormone binding globulin in postmenopausal women. International Journal of Obsesity Noyan V, Yucel A & Sagsoz N. The association of androgenic sex steroids with serum lipid levels in postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica Dobiasova M & Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in ApoB-lipoprotein-depleted plasma (FER HDL ). Clinical Biochemistry Cleeman J. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association Oh JY, Barrett-Connor E, Wedick NM & Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care Goodman-Gruen D & Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care Khaw KT & Barrett-Connor E. Fasting plasma glucose levels and endogenous androgens in non-diabetic postmenopausal women Clinical Science Maturana MA & Spritzer PM. Association between hyperinsulinemia and endogenous androgen levels in peri- and postmenopausal women. Metabolism Golden S, Ding J, Szklo M, Schmidt MI, Duncan BB & Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women. The Atherosclerosis Risk in Communities Study. American Journal of Epidemiology Hughes GS, Mathur RS & Margolius HS. Sex steroid hormones are altered in essential hypertension. Journal of Hypertension Phillips GB, Pinkernell BH & Jing TY. Relationship between sex hormones and coronary artery disease in postmenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology Phillips GB, Tuck CH, Jing TY, Boden-Albala B, Lin IF, Dahodwala N & Sacco RL. Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women. Diabetes Care Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, Korenman S, Lasley WL, Luborsky JL, McConnell D, Sowers MF & Weiss G. Correlates of circulating androgens in mid-life women: the study of women s health across the nation. Journal of Clinical Endocrinology and Metabolism Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H & Szklo M. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the Atherosclerosis Risk in Communities Cohort. American Journal of Epidemiology Received 10 January 2006 Accepted 20 March 2006
The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationROKSANA KARIM, MBBS, PHD UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES, CA
Gonadotropin and Sex Steroid Levels in HIVinfected Premenopausal Women and Their Association with Subclinical Atherosclerosis in HIVinfected and -uninfected Women in the Women s Interagency HIV Study (WIHS)
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationHormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index
Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationSex Hormones in Postmenopausal Women Receiving Low-Dose Hormone Therapy: The Effect of BMI
nature publishing group Sex Hormones in Postmenopausal Women Receiving Low-Dose Hormone Therapy: The Effect of BMI Irene Lambrinoudaki 1, Eleni Armeni 1, Demetrios Rizos 2, Eythimios Deligeoroglou 1, Panagiotis
More informationHBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS
Original Article HBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS Chintamani Bodhe*, Deepali Jankar**, Tara Bhutada***, Milind Patwardhan****, Mrs Varsha Patwardhan***** ABSTRACT
More informationa Departments of Clinical Sciences in Lund and b Malmö, Lund University, Lund, Sweden
Do sex hormones influence features of the metabolic syndrome in middle-aged women? A populationbased study of Swedish women: The Women s Health in the Lund Area (WHILA) Study Yasameen A. Shakir, M.D.,
More informationThe effects of soy protein in women and men with elevated plasma lipids 1
BioFactors 12 (2000) 251 257 251 IOS Press Original report The effects of soy protein in women and men with elevated plasma lipids 1 R. Mackey a, A. Ekangaki a and J.A. Eden b, a Sydney Menopause Centre,
More informationThe Effect of Postmenopausal Ovarian Volume on Lipid and Hormonal Levels
Med. J. Cairo Univ., Vol. 8, No. 2, September: 31-35, 212 www.medicaljournalofcairouniversity.com The Effect of Postmenopausal Ovarian Volume on Lipid and Hormonal Levels AHMED SALEH, M.D.*; AHMED SOLIMAN,
More informationMetabolic changes in menopausal transition
Metabolic changes in menopausal transition Terhi T. Piltonen M.D., Associate Professor Consultant, Clinical Researcher for the Finnish Medical Foundation Department of Obstetrics and Gynecology PEDEGO
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationMETABOLIC SYNDROME IN REPRODUCTIVE FEMALES
METABOLIC SYNDROME IN REPRODUCTIVE FEMALES John J. Orris, D.O., M.B.A Division Head, Reproductive Endocrinology & Infertility, Main Line Health System Associate Professor, Drexel University College of
More informationWomen are known to suffer coronary heart disease 10 to
Sex Hormone Binding Globulin and the Free Androgen Index Are Related to Cardiovascular Risk Factors in Multiethnic Premenopausal and Perimenopausal Women Enrolled in the Study of Women Across the Nation
More informationEffects of the Transition from Premenopause to Postmenopause on Lipids and Lipoproteins: Quantification and Related Parameters
ORIGINAL ARTICLE DOI: 10.3904/kjim.2011.26.1.47 Effects of the Transition from Premenopause to Postmenopause on Lipids and Lipoproteins: Quantification and Related Parameters Eun Jeung Cho 1, Yun Joo Min
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationLipid Profile and Menopausal Status * Fouad Hamad Al - Dahhan FRCOG # Lamia M. Al - Naama Ph.D Med. Bioch. UK *Ahlam Disher CAB Gyn & Ob
Lipid Profile and Menopausal Status * Fouad Hamad Al - Dahhan FRCOG # Lamia M. Al - Naama Ph.D Med. Bioch. UK *Ahlam Disher CAB Gyn & Ob Abstract Background: Dyslipidemia is a major cause of cardiovascular
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationCARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME
CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child
More informationCARDIOVASCULAR RISK FACTORS. Harpal S Randeva. Warwick Medical School University of Warwick, UK
NORDIC FEDERATION OF SOCIETIES OF OBSTETRICS AND GYNAECOLOGY November, 2010 POLYCYSTIC OVARY SYNDROME THROUGH LIFE CARDIOVASCULAR RISK FACTORS Harpal S Randeva Warwick Medical School University of Warwick,
More informationKaren Olson, 1 Bryan Hendricks, 2 and David K. Murdock Introduction. 2. Methods
Cholesterol Volume 2012, Article ID 794252, 4 pages doi:10.1155/2012/794252 Research Article The Triglyceride to HDL Ratio and Its Relationship to Insulin Resistance in Pre- and Postpubertal Children:
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationResearch Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers
International Inflammation Volume 2012, Article ID 124693, 5 pages doi:10.1155/2012/124693 Research Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers Yaron Arbel,
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationSex hormones, sex hormone binding globulin, and abdominal aortic calcification in women and men in the multi-ethnic study of atherosclerosis (MESA)
Atherosclerosis 200 (2008) 432 438 Sex hormones, sex hormone binding globulin, and abdominal aortic calcification in women and men in the multi-ethnic study of atherosclerosis (MESA) Erin D. Michos a,,
More informationEndogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy
European Journal of Endocrinology (2007) 156 687 693 ISSN 0804-4643 CLINICAL STUDY Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy Erik Debing 1, Els Peeters
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationARIC STUDY MANUSCRIPT PROPOSAL # 714. PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority:
1 ARIC STUDY MANUSCRIPT PROPOSAL # 714 PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority: 1. a. Full Title: Effect of menopausal status on mood: The influence of demographic
More informationAttendee become familiar with the evidence for the major risk factors for CVD Attendee will become familiar with the
PCOS Cardiovascular Health (Post( Post-Reproductive Life) Robert A. Wild, M.D., Ph.D., M.P.H Professor and Chief Gynecology Professor Clinical Epidemiology Department of Obstetrics and Gynecology VA Medical
More information10 Essential Blood Tests PART 2
Presents 10 Essential Blood Tests PART 2 The Blood Chemistry Webinars With DR. DICKEN WEATHERBY Creator of the Blood Chemistry Software Heart Disease, Inflammation, & Essential Blood Tests #2 to #4: Fibrinogen,
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationTestosterone, SHBG and cardiovascular health in postmenopausal women
Master s thesis Testosterone, SHBG and cardiovascular health in postmenopausal women OH O Student: Judith Brand Student number: 0509744 Master s programme: Epidemiology, Clinical Epidemiology, Utrecht
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationMethods and Baseline Cardiovascular Data From the Early Versus Late Intervention Trial With Estradiol Testing the Menopausal Hormone Timing Hypothesis
Methods and Baseline Cardiovascular Data From the Early Versus Late Intervention Trial With Estradiol Testing the Menopausal Hormone Timing Hypothesis Howard N. Hodis, MD, Wendy J. Mack, PhD, Donna Shoupe,
More informationComparative Analysis Of Atherogenic Index Of Plasma And Its Relationship With...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 8 Ver. VIII (Aug. 2015), PP 102-107 www.iosrjournals.org Comparative Analysis Of Atherogenic
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationADVANCED CARDIOMETABOLIC SCREENING
ADVANCED CARDIOMETABOLIC SCREENING INTRODUCTION SignatureMD and its affiliated physicians continuously seek out technology to identify health risk factors before they become serious diseases. SignatureMD
More informationRisks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome
de Medeiros Reproductive Biology and Endocrinology (2017) 15:93 DOI 10.1186/s12958-017-0313-y REVIEW Open Access Risks, benefits size and clinical implications of combined oral contraceptive use in women
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationRELATIONSHIP BETWEEN BMI, TOTAL TESTOSTERONE, SEX HORMONE-BINDING-GLOBULIN, LEPTIN, INSULIN AND INSULIN RESISTANCE IN OBESE MEN
Archives of Andrology, 52:355 361, 2006 Copyright # Informa Healthcare ISSN: 0148-5016 print/1521-0375 online DOI: 10.1080/01485010600692017 RELATIONSHIP BETWEEN BMI, TOTAL TESTOSTERONE, SEX HORMONE-BINDING-GLOBULIN,
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationsphingotest vr-hgh Risk Prediction of Incident Cardiovascular Disease
sphingotest vr-hgh Risk Prediction of Incident Cardiovascular Disease Human Growth Hormone as Vascular Risk Biomarker sphingotec offers the vascular risk human Growth Hormone biomarker (vr-hgh) for the
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationClinical Manifestations of the Polycystic Ovary Syndrome at Menopausal Age
American Journal of Medicine and Medical Sciences 2019, 9(1): 35-39 DOI: 10.5923/j.ajmms.20190901.06 Clinical Manifestations of the Polycystic Ovary Syndrome at Menopausal Age Gafurova F. A. Assistant
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationStudy of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults
Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults Z.-P. Li 1, M. Zhang 2, J. Gao 3, G.-Y. Zhou 3, S.-Q. Li 1 and Z.-M. An 3 1 Golden
More informationLipoprotein (a): Is it important for Friedewald formula?
ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry
More informationSerum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online June 9, 2009 Serum uric acid and incident DM2 Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting
More informationLEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME
LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME Diana A. Chirinos, Ronald Goldberg, Elias Querales-Mago, Miriam Gutt, Judith R. McCalla, Marc Gellman and Neil Schneiderman
More informationThoughts on PCOS Female Androgenization Syndrome FAS
Thoughts on PCOS Female Androgenization Syndrome FAS Stan Korenman, M.D. Distinguished Professor of Medicine-Endocrinology and Associate Dean - Ethics David Geffen School of Medicine at UCLA Conflicts
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More informationGonadal Dysfunction with Postprandial Hypertriglyceridemia is Risk Predictor of Cardiovascular Disease in Men with Type 2 Diabetes Mellitus
Iraqi JMS Published by Al-Nahrain College of Medicine ISSN 1681-6579 Email: iraqijms@colmed-alnahrain.edu.iq http://www.colmed-nahrain.edu.iq Gonadal Dysfunction with Postprandial Hypertriglyceridemia
More informationTherapeutic Cohort Results
Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7
More informationReproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)
Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD) Pr Sophie Christin-Maitre Reproductive Endocrine Unit, Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie INSERM U933 Paris, France
More informationStudy No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationTESTOSTERONE AND CARDIOVASCULAR RISK IN MEN 685
TESTOSTERONE AND CARDIOVASCULAR RISK IN MEN 685 and bioavailable testosterone, SHBG, insulin, and cardiovascular risk factors in men, intervention studies are needed. Up to now, few clirùcal trials have
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationGender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity
71 P.P.Bidzilya Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine
More informationBlood Pressure Measurement (children> 3 yrs)
Blood Pressure Measurement (children> 3 yrs) If initial BP elevated, repeat BP manually 2x and average, then classify Normal BP Systolic and diastolic
More informationTechnical Information Guide
Technical Information Guide This Guide provides information relating to the selection, utilization, and interpretation of the Quantose IR test. Information provided is based on peer-reviewed publications
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationRotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?
Disclosure Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause? Fractyl laboratories, Inc Anuja Dokras, MD., Ph.D. Professor of Obstetrics and Gynecology Director PENN PCOS
More informationCardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010
Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 CAVEAT LECTOR 2 CVD-related Mortality in Aging SCI GU
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationDYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul
More informationASSOCIATIONS BETWEEN C-REACTIVE PROTEIN, PHYSICAL ACTIVITY, AND OTHER CARDIAC RISK FACTORS IN POSTMENOPAUSAL WOMEN. Beth M.
ASSOCIATIONS BETWEEN C-REACTIVE PROTEIN, PHYSICAL ACTIVITY, AND OTHER CARDIAC RISK FACTORS IN POSTMENOPAUSAL WOMEN by Beth M. Larouere BS Degree Physical Education- Exercise Science, Slippery Rock University,
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationOne Day Hormone Check
One Day Hormone Check DOB: Sex: F MRN: Order Number: Completed: Received: Collected: Salivary Hormone Results Estradiol pmol/l >3330.0 Testosterone pmol/l
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Study on Assessment of Testosterone, Insulin Resistance and HbA1c in Women with Polycystic
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationMetabolic dysfunction in obese Hispanic women with PCOS
Metabolic dysfunction in obese Hispanic women with PCOS 1 Metabolic dysfunction in obese Hispanic women with PCOS Susan Sam 1, Bert Scoccia 2, Sudha Yalamanchi 3, Theodore Mazzone 1,4 1 Department of Medicine,
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationAssociation Between Sex Hormones and Adiposity: Qualitative Differences in Women and Men in the Multi-Ethnic Study of Atherosclerosis
JCEM Brief ONLINE Report Association Between Sex Hormones and Adiposity: Qualitative Differences in Women and Men in the Multi-Ethnic Study of Atherosclerosis Morgana L. Mongraw-Chaffin, Cheryl A. M. Anderson,
More information. Non HDL-c : Downloaded from ijdld.tums.ac.ir at 18:05 IRDT on Friday March 22nd Non HDL LDL. . LDL Non HDL-c
208-23 (2 ) 0 389 -. Non HDL * Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 Non HDL : LDL.. 5 3277 :.. odds ratio Chi-Square %3/9 Non HDL-C %2 LDL-C. %3 : Non-HDL-C LDL-C. (CI
More informationSex Steroid Levels and Response to Weight Loss Interventions among Postmenopausal Women in the Diabetes Prevention Program
Sex Steroid Levels and Response to Weight Loss Interventions among Postmenopausal Women in the Diabetes Prevention Program Catherine Kim 1, Elizabeth Barrett-Connor 2, John F. Randolph 3, Shengchun Kong
More informationAdiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance.
ORIGINAL ARTICLE Adiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance. Bonneau GA y Pedrozo WR 1 Ministry of Public Health, Province of Misiones, 2 School of Exact, Chemical
More information